View in EDS

Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.

Saved in:
Bibliographic Details
Title: Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.
Authors: Morand EF; Centre for Inflammatory Diseases, Monash University, Melbourne, VIC, Australia. Electronic address: eric.morand@monash.edu., Dall'Era M; Division of Rheumatology, University of California San Francisco School of Medicine, San Francisco, CA, USA., Sanchez-Guerrero J; Division of Rheumatology, Mount Sinai Hospital and Toronto Western Hospital, University of Toronto, Toronto, ON, Canada., Pearson DR; Department of Dermatology, University of Minnesota, Minneapolis, MN, USA., Werth VP; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J Crescenz VAMC, Philadelphia, PA, USA., Wenzel J; Department of Dermatology and Allergy, Cluster of Excellence ImmunoSensation(3), University Hospital of Bonn, Bonn, Germany., Roy S; Ares Trading, Eysins, Switzerland, an affiliate of Merck., Kleinmond C; Merck Healthcare, Darmstadt, Germany., Gühring H; Merck Healthcare, Darmstadt, Germany., Sgouroudi E; Merck Healthcare, Darmstadt, Germany., Klopp-Schulze L; Merck Healthcare, Darmstadt, Germany., Moreau F; EMD Serono Research and Development Institute, Billerica, MA, USA, an affiliate of Merck., Fernandez-Ruiz R; EMD Serono Research and Development Institute, Billerica, MA, USA, an affiliate of Merck., Furie R; Northwell, New Hyde Park, NY; Division of Rheumatology, Northwell, Great Neck, NY, USA.
Source: Lancet (London, England) [Lancet] 2026 May 09; Vol. 407 (10541), pp. 1809-1824.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42107374
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Morand+EF%22">Morand EF</searchLink>; Centre for Inflammatory Diseases, Monash University, Melbourne, VIC, Australia. Electronic address: eric.morand@monash.edu.<br /><searchLink fieldCode="AU" term="%22Dall'Era+M%22">Dall'Era M</searchLink>; Division of Rheumatology, University of California San Francisco School of Medicine, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sanchez-Guerrero+J%22">Sanchez-Guerrero J</searchLink>; Division of Rheumatology, Mount Sinai Hospital and Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Pearson+DR%22">Pearson DR</searchLink>; Department of Dermatology, University of Minnesota, Minneapolis, MN, USA.<br /><searchLink fieldCode="AU" term="%22Werth+VP%22">Werth VP</searchLink>; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J Crescenz VAMC, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Wenzel+J%22">Wenzel J</searchLink>; Department of Dermatology and Allergy, Cluster of Excellence ImmunoSensation(3), University Hospital of Bonn, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Roy+S%22">Roy S</searchLink>; Ares Trading, Eysins, Switzerland, an affiliate of Merck.<br /><searchLink fieldCode="AU" term="%22Kleinmond+C%22">Kleinmond C</searchLink>; Merck Healthcare, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Gühring+H%22">Gühring H</searchLink>; Merck Healthcare, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Sgouroudi+E%22">Sgouroudi E</searchLink>; Merck Healthcare, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Klopp-Schulze+L%22">Klopp-Schulze L</searchLink>; Merck Healthcare, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Moreau+F%22">Moreau F</searchLink>; EMD Serono Research and Development Institute, Billerica, MA, USA, an affiliate of Merck.<br /><searchLink fieldCode="AU" term="%22Fernandez-Ruiz+R%22">Fernandez-Ruiz R</searchLink>; EMD Serono Research and Development Institute, Billerica, MA, USA, an affiliate of Merck.<br /><searchLink fieldCode="AU" term="%22Furie+R%22">Furie R</searchLink>; Northwell, New Hyde Park, NY; Division of Rheumatology, Northwell, Great Neck, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2026 May 09; Vol. 407 (10541), pp. 1809-1824.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42107374
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(26)00463-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1809
    Titles:
      – TitleFull: Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Morand EF
      – PersonEntity:
          Name:
            NameFull: Dall'Era M
      – PersonEntity:
          Name:
            NameFull: Sanchez-Guerrero J
      – PersonEntity:
          Name:
            NameFull: Pearson DR
      – PersonEntity:
          Name:
            NameFull: Werth VP
      – PersonEntity:
          Name:
            NameFull: Wenzel J
      – PersonEntity:
          Name:
            NameFull: Roy S
      – PersonEntity:
          Name:
            NameFull: Kleinmond C
      – PersonEntity:
          Name:
            NameFull: Gühring H
      – PersonEntity:
          Name:
            NameFull: Sgouroudi E
      – PersonEntity:
          Name:
            NameFull: Klopp-Schulze L
      – PersonEntity:
          Name:
            NameFull: Moreau F
      – PersonEntity:
          Name:
            NameFull: Fernandez-Ruiz R
      – PersonEntity:
          Name:
            NameFull: Furie R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 05
              Text: 2026 May 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 407
            – Type: issue
              Value: 10541
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1